. The homogeneous protein had a concentration of 0.5 mg/ml in 10 mM sodium acetate buffer, pH 4.1 . Before injections, rhGCSF was diluted to the appropriate concentration in a final volume of 250 j ul in saline containing 0.1 % heat-inactivated autologous serum . Endotoxin levels were determined by the Limulus amebocyte lysate assay (Whittaker M . A . Bioproducts, Walkersville, MD) and were undetectable . The CSF activity of the protein (10' U/mg) was determined as described (5) . The rhGCSF was administered subcutaneously into alternate thighs.
Neutrophil Function Assays . Peripheral blood neutrophils were separated from heparinized blood by 3% gelatin sedimentation followed by fractionation over discontinuous Percoll (Pharmacia Fine Chemicals, Piscataway, NJ) gradients as described (6) , and neutrophils were recovered from the 75% layer . The cell concentration was adjusted to 10 6 cells/ml.
Chemotaxis was measured using a modification of the method of Boyden (7) . Briefly, blind well chambers were filled with zymosan (Sigma Chemical Co., St. Louis, MO) in HBSS, covered with 5-Am-pore membrane filter (Millipore Corp., Bedford, MA) and the top chamber filled with 2 X 10 5 neutrophils in HBSS containing 2% BSA (Sigma Chemical Co .) . After incubation (3 h, 37°C), the filters were fixed, stained with hematoxylin, and cleared in xylene . The number of neutrophils crossing the filter (lower surface) were counted using a light microscope (x400).
Nitroblue tetrazolium (NBT) reduction was tested according to a method described by Gifford (8) . Briefly, neutrophils were separated from a single drop of blood by their propensity to stick to glass, and were exposed to NBT and counterstained with nuclear fast red. Percentage ofcells containing intracellular blue formazan particles were counted using a light microscope .
Results and Discussion
Effects of rhG-CSF in Healthy Monkeys. The effects of rhG-CSF on hematopoiesis in vivo were determined initially in two monkeys receiving 10 wg/kg/d divided in two daily subcutaneous injections for 2-4 wk. The white blood cells (WBC) count and absolute neutrophil count (ANC) of a rhG-CSF-treated monkey and a control buffer-treated monkey are shown in Fig. 1 A. The WBC count in the treated monkey increased dramatically 24 h after initiation of treatment, and by day 6 reached a plateau between 4.2 X 10' and 5.6 X 104 cells/mm', with an ANC of between 3.1 X 10' and 4.2 X 10' cells/mm'. This WBC level was maintained throughout the remaining 3 wk of treatment. There was no significant change in the WBC or ANC of the control animal during the same treatment period (Fig. I A) . The second animal treated at 10 Ag/kg/d for 14 d showed a WBC increase from 9 X 10 5 cells/mm s to a level between 4.86 X 10' and 5.01 X 104 cells/mm' (Fig. I B) . The pattern of response to rhG-CSF in both monkeys receiving 10 icg/kg/d was very similar (Fig. 1, A and B) . To assess the dose response to rhG-CSF, the second monkey subsequently received a dose of 100 Ag/kg/d for an additional 2 wk (Fig. 1 B) . At 100 ug/kg/d, the WBC count ranged between 8.0 X 10' and 1 .20 X 10 5 cells/mm'. In addition, a third monkey was treated at 1 ug/kg/d for 15 d and exhibited a WBC plateau ranging from 1 .8 X 104 to 2.9 X 10' cells/mm' (Fig. 1 B) . These data indicate a dose-dependent increase in WBC and ANC. In both monkeys the WBC count returned to normal levels 3 d after rhGCSF treatment (data not shown) .
Analysis of the absolute numbers of peripheral blood neutrophils, lymphocytes, monocytes, erythrocytes, eosinophils, reticulocytes, and platelets was performed every other day. The increase in WBC was predominantly due to the increase of absolute numbers of neutrophils ( Fig. 1 A) . The absolute numbers of eosinophils 
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and monocytes did notchange significantly. There was a dose-dependent increase in the absolute number of lymphocytes (1 .5-2.5-fold) in monkeys receiving 10 .ug/kg/d or 100 ,ug/kg/d . The majority (~80%) of peripheral blood lymphocytes were found to be T cells, as assessed by reactivity with the anti-human T cell antibody TI 1 . No significant changes in erythrocyte, reticulocyte, or platelet counts or hemoglobin concentrations were noted.
The monkey receiving 10 ug/kg/d for 28 d and the control monkey were sacrificed on day 29. Before sacrifice, peripheral blood smears were made and stained (Giemsa) for differential cell counts ( Fig. 2A) . Neutrophils predominated in the blood smear from the rhG-CSF-treated monkey. Immediately after sacrifice, sternal bone marrow specimens were taken for histologic examination, serially dehydrated, and embedded in plastic for thin sectioning . Sections of the bone marrow from the treated monkey demonstrated hypercellularity and a predominance of neutrophil precursors (Fig. 2B) . The numbers of myeloblasts, promyelocytes, myelocytes, and bands were increased 5-10-fold over those in the specimen from the control monkey.
Extramedullary Hematopoiesis. The spleen of the increased in size or weight, but showed prominent white follicles on the subcapsular and cut surfaces. Histologically, the internodular areas were filled with mature granulocytes and foci of extramedullary myelopoiesis, demonstrating myeloblasts and myelocytes . Generally lymph nodes were increased twofold in size due to lymphoid hypercellularity, and occasional foci of extramedullary Hypocellularity is present in the specimen from the monkey that received only CY (1), whilethebone marrow smear from a similarly treated monkey, also given rhGCSF starting on the third day after the second dose of CY, shows normal cellularity, with all elements present and a predominance of granulocytes and their precursors (2). x 400. myelopoiesis (bands, myelocytes, promyelocytes, and myeloblasts) were observed . The thymus was moderately enlarged, and rare foci of myelopoiesis were noted. No other organs (e.g., liver, kidney, etc.) demonstrated evidence of hematopoietic activity . No toxicity was seen by clinical or laboratory examination.
TABLE I Peripheral Blood Neutrophil Functions of rhG-CSF-treated Monkeys
Peripheral blood neutrophil functions of control and rhGCSF (>>-10 kg/kg/d) treated monkeys . Peripheral blood neutrophils were isolated from monkeys on the 21st day of treatment, and separated as described (6) .
* Chemotaxis is measured as the number of neutrophils (mean of five random fields) crossing a 5-km filter using zymosan as the chemoattractant. The results are shown as mean t SD, with or without zymosan as the chemoattractant. * The percentage of neutrophils (>_ 100 cells examined) containing intracellular blue formazan particles.
Neutrophil Functions. In view of the dramatic peripheral blood neutrophilia in animals receiving rhG-CSF, we measured the neutrophil activities in vitro on the 21st day of treatment . As shown in Table I , the neutrophils of treated monkeys functioned normally in a standard test for chemotaxis. Neutrophils were then tested for their ability to reduce NBT as measured by the percentage of cells containing intracellular blue formazan particles .^-73% ofthe neutrophils recovered from treated animals contained intracellular blue formazan particles, whereas only 35% of the cells from the control animal contained such particles (Table I) . These results indicate that the expanded pool of neutrophils in treated animals are functionally normal and may have an enhanced ability kill to phagocytized bacteria .
Effects of rhG-CSF in CY-treated Monkeys. To test the effect of rhG-CSF in chemotherapy-induced cytopenia, we treated three monkeys with CY (60 mg/kg/d, two doses) . This dosage leads to bone marrow aplasia and peripheral blood pancytopenia by day 4-7 after treatment . Two of the three monkeys also received rhG-CSF (10 wg/kg/d), while the third received only CY . As shown in Fig . 3 , one monkey received rhG-CSF for 14 d, starting 72 h after the last dose of CY . By the day after the first day of rhG-CSF, the WBC count in this monkey rose from 2 .3 X 10 3 to 7 X 103 , and then fell to 4 X 102' and 3.7 X 10' in the subsequent 2 d. This brief rise in the WBC was most likely due to demargination of neutrophils . A second monkey was treated with rhG-CSF for 6 d before CY, during the CY administration, and for an additional 21 d. This monkey acquired a peripheral WBC level of 5.23 X 104 cells/mm' before CY treatment . The first dose of CY did not lead to an expected decrease of the peripheral WBC, but rather was followed by a continued increase to 7.1 X 10' cells/mm . The WBC counts declined in all three monkeys to a level under 2.5 X 103 cells/mm3 by day 4 after CY, and in the rhG-CSF-pretreated monkey, to a brief and transient nadir of 200 WBC by day 6. In both rhG-CSF-treated monkeys, the peripheral WBC increased dramatically by day 6-7 after CY, reaching levels of -5.0 X 104 WBC/mm3 by the IOth day after CY . These WBC levels are similar to those seen in normal monkeys receiving only rhG-CSF at the same dose. The ANC ranged between 90 and 100% from day 7 to day 20 after CY, while lymphocytes remained <10% and monocytes <2% during the same time period. After cessation of rhG-CSF administration, the WBC count never dropped below normal levels. The percentage of neutrophils also returned to normal values (30-40%) . In contrast, the control monkey remained pancytopenic, with WBC levels <4 X 10s cells/mms, up to 4 wk after CY treatment (Fig. 3) . As shown in Fig . 2C , the bone marrow aspirate (day 14 after CY) of the rhG-CSF-treated monkey showed evidence of recovery of all cell lineage precursors, whereas the control monkey (CY alone) demonstrated persistent hypocellularity . The time course of post-CY platelet recovery was similar in all three monkeys (rhG-CSFtreated or control), requiring^-2 wk to return to normal levels. The early recovery after CY suggests that the availability of this growth factor is one of the critical limiting steps in the proliferation and differentiation of bone marrow progenitor cells after CY treatment. The dramatic recovery of neutrophils in the rhG-CSF-treated monkeys after CY is also indicative of the functional integrity of progenitor cells capable of responding to rhG-CSF. These data suggest, however, that pretreatment with rhGCSF does not prevent CY-induced cytopenia when given in the regimen described herein .
Summary
We examined the in vivo effects of recombinant human granulocyte colonystimulating factor (rhG-CSF) in primates (cynomolgus monkeys) treated with subcutaneous doses of rhG-CSF for 14-28 d. A dose-dependent increase in the peripheral white blood cells (WBC) was seen, reaching a plateau after 1 wk of rhG-CSF treatment. The elevation of WBC was due to an increase in the absolute neutrophil count. These results demonstrate that rhG-CSF is a potent granulopoietic growth and differentiation factor in vivo . In cyclophosphamide (CY)-induced myelosuppression, rhG-CSF was able to shorten the time period of WBC recovery in two treated monkeys to 1 wk, as compared to more than 4 wk for the control monkey . Its ability to significantly shorten the period of chemotherapy-induced bone marrow hypoplasia may allow clinicians to increase the frequency or dosage of chemotherapeutic agents . In addition, the increase in absolute numbers of functionally active neutrophils may have a profound effect in the rate and severity of neutropenia-related sepsis. Furthermore, the activities reported here indicate a potential role for rhG-CSF in the treatment of patients with myelodysplastic syndrome, congenital agranulocytosis, radiation-induced myelosuppression, and bone marrow transplantation.
